Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Multiple Myeloma(MM) Clinical Trial

Official title: Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Status Unknown status

Clinical Trial Summary

• To investigate the safety and tolerability of OPB-31121 following repeated oral administration of OPB-31121 in patients Non-Hodgkin's Lymphoma(NHL) or Multiple Myeloma(MM)

• To determine the potential dose-limiting toxicities and maximum-tolerated dose in patients treated with OPB-31121

• To determine the pharmacokinetics and anti-tumor efficacy of OPB-31121 in patients

Clinical Trial Description

The study is designed as a single-center,open-label,phase 1 dose-escalation study to assess the safety,tolerability,pharmacokinetics, and anti-tumor efficacy of OPB-31121 in patients with relapsed or refractory NHL or MM.

• To investigate the safety and tolerability of OPB-31121 following repeated oral administration of OPB-31121 in patients NHL or MM

• To determine the potential dose-limiting toxicities and maximum-tolerated dose in patients treated with OPB-31121

• To determine the pharmacokinetics and anti-tumor efficacy of OPB-31121 in patients ;

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Multiple Myeloma
• Multiple Myeloma(MM)
• Neoplasms, Plasma Cell
• Non-Hodgkin's Lymphoma(NHL)

• NCT number: NCT00511082
• Study type: Interventional
• Source: Otsuka Beijing Research Institute
• Contact: Shii Man, M.D & Ph.D.
• Phone: +86-10-85182966
• Email: mans@obri.otsuka.com
• Status: Unknown status
• Phase: Phase 1
• Start date: December 2007
• Completion date: December 2009